The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review.
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Adaptimmune Therapeutics Plc ADR is $260.97M. A total of 1.58 million shares were traded on the day, compared to an average of 1.26M shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, ADAP has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 0 SELLs from insiders. Insiders purchased 0 shares during that period but sold 0.
In the most recent transaction, Rawcliffe Adrian sold 30,080 shares of ADAP for 0.67 per share on Jan 17. After the transaction, the Chief Executive Officer now owns 44,848 company shares. In a previous transaction on Jan 17, Bertrand William C JR sold 18,908 shares at 0.67 per share. ADAP shares that Chief Operating Officer owns now total 7,785.
Among the insiders who sold shares, Norry Elliot disposed of 18,276 shares on Jan 17 at a per-share price of $0.67. This resulted in the Chief Medical Officer holding 7,785 shares of ADAP after the transaction. In another insider transaction, Lunger John sold 18,114 shares at $0.67 per share on Jan 17. Company shares held by the Chief Patient Supply Officer now total 7,785.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for ADAP in the last 3 months, the mean price target is $3.60 with high estimates of $9.00 and low estimates of $1.00. In terms of 52-week highs and lows, ADAP has a high of $1.85 and a low of $0.42.
As of this writing, ADAP has an earnings estimate of $Advance Auto Parts Inc. per share for the current quarter. EPS was calculated based on a consensus of Adaptimmune Therapeutics plc estimates, with a high estimate of $EDAP TMS S.A. per share and a lower estimate of $Automatic Data Processing, Inc.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ADAP’s latest balance sheet shows that the firm has $369.58M in Cash & Short Term Investments as of fiscal 2021. There were $25.47M in debt and $62.54M in liabilities at the time. Its Book Value Per Share was $0.39, while its Total Shareholder’s Equity was $205.96M.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ADAP is Buy with a score of 3.67.